Literature DB >> 21225217

Treatment of severe chromoblastomycosis with itraconazole and 5-flucytosine association.

Vicente Sperb Antonello1, Marcelo Campos Appel da Silva, Eduardo Cambruzzi, Dimas Alexandre Kliemann, Breno Riegel Santos, Flávio Queiroz-Telles.   

Abstract

Chromoblastomycosis is a chronic human melanized fungi infection of the subcutaneous tissue caused by traumatic inoculation of a specific group of dematiaceous fungi through the skin, often found in barefooted agricultural workers, in tropical and subtropical climate countries. We report the case of a male patient presenting a slow-growing pruriginous lesion on the limbs for 20 years, mistreated over that time, which was diagnosed and successfully treated as chromoblastomycosis. Besides the prevalence of this disease, treatment is still a clinical challenge.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21225217     DOI: 10.1590/s0036-46652010000600008

Source DB:  PubMed          Journal:  Rev Inst Med Trop Sao Paulo        ISSN: 0036-4665            Impact factor:   1.846


  8 in total

Review 1.  Chromoblastomycosis.

Authors:  Flavio Queiroz-Telles; Sybren de Hoog; Daniel Wagner C L Santos; Claudio Guedes Salgado; Vania Aparecida Vicente; Alexandro Bonifaz; Emmanuel Roilides; Liyan Xi; Conceição de Maria Pedrozo E Silva Azevedo; Moises Batista da Silva; Zoe Dorothea Pana; Arnaldo Lopes Colombo; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2017-01       Impact factor: 26.132

Review 2.  CHROMOBLASTOMYCOSIS: A NEGLECTED TROPICAL DISEASE.

Authors:  Flavio Queiroz-Telles
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2015-09       Impact factor: 1.846

3.  Combination of Amphotericin B and Terbinafine against Melanized Fungi Associated with Chromoblastomycosis.

Authors:  S Deng; W Lei; G S de Hoog; L Yang; R G Vitale; H Rafati; M Seyedmousavi; A Tolooe; H van der Lee; W Liao; P E Verweij; S Seyedmousavi
Journal:  Antimicrob Agents Chemother       Date:  2018-05-25       Impact factor: 5.191

Review 4.  Challenges in the therapy of chromoblastomycosis.

Authors:  Flavio Queiroz-Telles; Daniel Wagner de C L Santos
Journal:  Mycopathologia       Date:  2013-05-02       Impact factor: 2.574

Review 5.  Chromoblastomycosis: an etiological, epidemiological, clinical, diagnostic, and treatment update.

Authors:  Arival Cardoso de Brito; Maraya de Jesus Semblano Bittencourt
Journal:  An Bras Dermatol       Date:  2018 Jul-Aug       Impact factor: 1.896

Review 6.  Reviewing the Etiologic Agents, Microbe-Host Relationship, Immune Response, Diagnosis, and Treatment in Chromoblastomycosis.

Authors:  Luiz Felipe Domingues Passero; Italo Novais Cavallone; Walter Belda
Journal:  J Immunol Res       Date:  2021-11-01       Impact factor: 4.818

7.  New possibilities for chromoblastomycosis and phaeohyphomycosis treatment: identification of two compounds from the MMV Pathogen Box® that present synergism with itraconazole.

Authors:  Rowena Alves Coelho; Gabriela Machado Alves; Maria Helena Galdino Figueiredo-Carvalho; Fernando Almeida-Silva; Gabriela Rodrigues de Souza; Maria Cristina da Silva Lourenço; Fábio Brito-Santos; Ana Claudia Fernandes Amaral; Rodrigo Almeida-Paes
Journal:  Mem Inst Oswaldo Cruz       Date:  2022-09-12       Impact factor: 2.747

8.  Molecular identification and antifungal susceptibility profiles of clinical strains of Fonsecaea spp. isolated from patients with chromoblastomycosis in Rio de Janeiro, Brazil.

Authors:  Rowena Alves Coelho; Fábio Brito-Santos; Maria Helena Galdino Figueiredo-Carvalho; Juliana Vitoria Dos Santos Silva; Maria Clara Gutierrez-Galhardo; Antonio Carlos Francesconi do Valle; Rosely Maria Zancopé-Oliveira; Luciana Trilles; Wieland Meyer; Dayvison Francis Saraiva Freitas; Rodrigo Almeida-Paes
Journal:  PLoS Negl Trop Dis       Date:  2018-07-26
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.